Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

NCT07565428 is registered in ClinicalTrials.gov with Minerva Neurosciences as lead sponsor.

NCT NCT07565428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07565428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Lead sponsor
Minerva Neurosciences
Phase
Phase 3
Overall status
Recruiting
Start date
April 23, 2026
Completion date
December 31, 2028
Enrollment
380 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

negative symptoms of schizophrenia